Senate Resolution No. 2587

BY: Senator HOYLMAN-SIGAL

COMMEMORATING the 175th Anniversary of Pfizer,
Inc., and recognizing the company's service to the
citizens of the State of New York and the World

WHEREAS, It is the sense of this Legislative Body to recognize the
achievements of those individuals and businesses that substantially
contribute to the economic vitality of their communities, thereby
enhancing the economic well-being of the entire Empire State; and

WHEREAS, Attendant to such concern, and in full accord with its
long-standing traditions, this Legislative Body is justly proud to
commemorate the 175th Anniversary of Pfizer, Inc.; and

WHEREAS, Pfizer is a research-based global pharmaceutical company,
headquartered in New York State, whose mission is to advance
breakthroughs that improve patients' lives; and

WHEREAS, Across New York State, Pfizer employs more than 6,000
colleagues and contracted employees, manages clinical trial and
investigator sites, and invests in strategic partnerships and external
research efforts with small biotech companies and universities; and

WHEREAS, Located in Pearl River, New York, the Pfizer Vaccine
Research and Development facility develops first-in-class and
best-in-class vaccines against diseases of significant importance to
public health, impacting all ages and geographies, and Pearl River
scientists are working to develop vaccines against serious infectious
diseases as well as cancer therapeutics; and

WHEREAS, Pfizer, Inc., has established the School of Science program
at its headquarters in New York City, designed to inspire the next
generation of scientists at an early age; and

WHEREAS, In 1849, Pfizer, Inc., was founded by Charles Pfizer and
Charles Erhart when they opened a fine-chemicals company in Brooklyn,
New York; and

WHEREAS, In 1941, Pfizer, Inc., responded to an appeal from the
United States Government to expedite the manufacture of penicillin for
the treatment of allied soldiers fighting in World War II; and

WHEREAS, For the past 175 years, Pfizer, Inc., has been at the
forefront of innovation and the acceleration of scientific advancements;
today, there are more than 300 Pfizer medicines across the globe; and

WHEREAS, Every day, the colleagues of Pfizer, Inc., work across both
developed and emerging markets to advance wellness, prevention,
treatments, and cures that challenge the most feared diseases of our
time; consistent with the company's responsibility as one of the world's
premier innovative biopharmaceutical companies, the company is
collaborating with healthcare providers, governments, and local
communities to support and expand access to reliable, affordable health
care around the world; and


WHEREAS, Pfizer, Inc., has an extensive history in vaccine research
and development, taking bold, new approaches to translate scientific
research into medicines for people fighting cancer, working toward
developing potential therapies for cardiometabolic diseases and
inflammatory diseases, helping to ensure that patients have access to
critical anti-infective therapies, and pioneering science that aims to
address unmet medical needs for patients with rare diseases; and

WHEREAS, The industry-leading portfolio and extensive pipeline of
Pfizer, Inc., include core mechanisms of action to attack cancer from
multiple angles, including molecules, antibody-drug conjugates (ADCs),
bispecific antibodies, and other immune-oncology biologics; and

WHEREAS, Pfizer, Inc., exemplifies its purpose by sourcing the best
science in the world, partnering with others in the healthcare system to
help improve access to its medicines, using digital technologies to
enhance its drug discovery and development, as well as patient outcomes,
and leading the conversation to advocate for innovation and patient
policies; and

WHEREAS, Pfizer, Inc., works with policy leaders, regulatory
agencies, healthcare providers, healthcare associations, distributors,
insurers, pharmacies, patient advocacy groups, and other pharmaceutical
companies to combat the risk which counterfeit medicines pose to the
health of our communities; and

WHEREAS, The Pfizer Multicultural Health Equity Collective (MHEC), a
cooperative of Pfizer colleagues and more than 40 non-profit partners
across the United States, including community groups, healthcare
provider associations, legislative caucuses, and patient advocacy
groups, has created "An Action Guide to Disrupt Inequitable Health
Outcomes," which highlights actionable solutions to disrupt drivers of
health inequities across four key areas--Healthcare Facilities &
Delivery, Research and Data, Workforce Pathways, and Policy; and

WHEREAS, Access to medicine is a cornerstone of commitment to health
care; Pfizer RxPathways connects eligible patients in the United States
to a range of its assistance programs that provide insurance support,
co-pay assistance, and medicines for low or no cost; and

WHEREAS, Pfizer, Inc., is working to reduce the environmental impact
of its medicines, advance diversity, and address health disparities to
create a healthier and more equitable world; and

WHEREAS, On this auspicious occasion of the 175th Anniversary, the
members of this Legislative Body extend special recognition to Pfizer,
Inc., for its record of service to the citizens of the State of New York
and the World; now, therefore, be it

RESOLVED, That this Legislative Body pause in its deliberations to
commemorate the 175th Anniversary of Pfizer, Inc.; and be it further

RESOLVED, That a copy of this Resolution, suitably engrossed, be
transmitted to Pfizer, Inc.